Research news last week included Rocket Pharmaceuticals suffering a setback with its Phase II trial of RP-A501, which ...

With an unchanged $10 price target, H.C. Wainwright maintained its Buy rating on Sangamo Therapeutics, Inc. (NASDAQ: SGMO) on ...

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

Over the past few decades, rapid progress in both tissue engineering and regenerative medicine has revolutionized approaches to tissue regeneration and ...

Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. ("Savara" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ...

This spring, the National Institutes of Health quietly began terminating programs at scores of colleges that prepared ...